Pharmacogenomics of Drug Interactions

Drug-drug interactions and inherited genetic variation often act on the same enzymes and transporters, so genotype can amplify, mask, or modify an interaction. This topic examines how pharmacogenomic variation interacts with co-administered medicines, including the phenomenon of phenoconversion, in which an inhibiting or inducing drug converts a genetically normal metaboliser into a functionally abnormal one.

Definition

The pharmacogenomics of drug interactions is the study of how inherited variation in drug-metabolising enzymes, transporters, and targets modifies the magnitude and clinical effect of interactions between co-administered medicines.

Scope

The entry covers the overlap between pharmacogenetics and drug-drug interactions: shared metabolic pathways, the concept of phenoconversion, and how genotype changes the clinical significance of an interaction. It explains why predicting interaction outcomes can require both the genotype and the concurrent medication list. It is reference-educational and provides no dosing or co-prescribing instructions.

Core questions

• How do genotype and co-medication jointly determine a patient's drug exposure?
• What is phenoconversion and when does it matter?
• Why can the same interaction be clinically important in one genotype and trivial in another?
• How are combined drug-gene-drug effects studied and described?

Key concepts

• Phenoconversion
• Shared CYP and transporter pathways
• Enzyme inhibition and induction
• Drug-gene-drug (combined) effects
• Predicted versus observed metaboliser phenotype
• Active-metabolite-dependent interactions

Mechanisms

Most clinically important interactions and many pharmacogenetic effects converge on a small set of metabolising enzymes and transporters. When an inhibitor blocks an enzyme, a patient with a fully functional genotype can behave like a poor metaboliser, a shift called phenoconversion; conversely, an inducer can raise clearance and offset a genetically reduced capacity. The net exposure therefore depends on the interaction of genotype with the concurrent drug. For prodrugs that require enzymatic activation, the same logic can reduce efficacy rather than increase toxicity, because the active species is not formed.

Clinical relevance

Because interactions and genotype share pathways, considering only one can give an incomplete picture of a patient's drug exposure, which is relevant to how adverse-reaction risk is understood. This topic explains those combined effects for educational appraisal of the evidence and mechanisms; it is not a source of co-prescribing, dosing, or interaction-management advice for individuals.

Epidemiology

The enzymes most often involved, such as CYP2D6, CYP2C19, and CYP3A, are both highly polymorphic and frequent targets of inhibitor and inducer drugs, so the opportunity for combined drug-gene-drug effects is common in polypharmacy. The frequency of relevant alleles varies across populations, and the prevalence of interacting co-medications varies by clinical setting.

Evidence & guidelines

Evidence comes from pharmacokinetic studies, mechanistic reviews, and consortium guidelines that increasingly note phenoconversion when translating genotype into phenotype, for example in guidance on CYP2D6 and CYP2C19 substrates. These resources describe how combined effects are accounted for in principle and lie outside the individualized scope of this reference.

History

As cytochrome P450 pharmacogenetics matured in the 1990s and 2000s, it became clear that the predicted phenotype from genotype alone could be overridden by interacting drugs. The concept of phenoconversion was articulated to capture this, and modern implementation guidelines have begun to incorporate co-medication when inferring metaboliser status, reflecting the integration of interaction science with pharmacogenomics.

Debates

Should genotype-to-phenotype translation routinely incorporate co-medication?

Phenoconversion can substantially change predicted metaboliser status, but systematically accounting for every interacting drug is complex; how far guidelines and decision-support tools should formalise this remains under discussion.

Key figures

• Grant Wilkinson
• Richard Weinshilboum
• Howard McLeod
• J. Kevin Hicks

Seminal works

• wilkinson-2005
• wang-2011

Frequently asked questions

What is phenoconversion?

It is a temporary shift in a patient's effective metaboliser status caused by an interacting drug; for example, a strong enzyme inhibitor can make a genetically normal metaboliser behave like a poor metaboliser while the inhibitor is present.

Why isn't genotype enough to predict an interaction's effect?

Because co-administered inhibitors or inducers can override the activity expected from genotype alone, the combined drug-gene-drug picture, not the genotype by itself, determines the actual drug exposure.